fda retatrutide Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation Retatrutide for Weight Loss: TRIUMPH-1

When making this switch, the GLP-1 receptor activity remains engaged since you are not starting from scratch

This leads to researchers using solutions well beyond their safe shelf life, with degraded potency they cannot detect visually

To this end, we often prescribe GLP-1 agonists, specifically Semaglutide GLP-1 and Liraglutide, due to their efficacy in reducing blood glucose levels and promoting weight loss

Eating smaller meals and avoiding fatty foods for the first few days after each injection can also help your body adjust

confirm all-in $149 price includes medication before first charge FDA regulatory status (as of June 2026): FDA formally proposed on April 30, 2026 removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulks list (Federal Register notice published May 1, 2026: 91 Fed

Visits are frequent